Covidien Makes Deal With Watson To Allow Generic Exalgo

Law360, New York (January 25, 2012, 7:57 PM EST) -- Zalicus Inc. on Wednesday said Covidien PLC, with which it partners on Covidien's painkiller Exalgo, has agreed to a settlement with Watson Pharmaceuticals Inc. that will allow a generic version of Exalgo to hit the market before the expiration of Covidien's patent.

Under the terms of the settlement between Covidien subsidiary Mallinckrodt Inc. and Watson Pharmaceuticals Inc.-Florida, Watson can introduce a generic version of hydromorphone hydrochloride extended-release tablets on Nov. 15, 2013, several months before the July 7, 2014 expiration of the patent covering the tablets,...
To view the full article, register now.